The estimated Net Worth of Kevin J. Ballinger is at least $14.5 Million dollars as of 5 March 2024. Kevin Ballinger owns over 11,700 units of Shockwave Medical stock worth over $5,960,893 and over the last 12 years Kevin sold SWAV stock worth over $8,536,213.
Kevin has made over 62 trades of the Shockwave Medical stock since 2013, according to the Form 4 filled with the SEC. Most recently Kevin bought 11,700 units of SWAV stock worth $198,783 on 5 March 2024.
The largest trade Kevin's ever made was exercising 111,807 units of Shockwave Medical stock on 27 April 2016 worth over $1,016,326. On average, Kevin trades about 13,572 units every 52 days since 2013. As of 5 March 2024 Kevin still owns at least 17,807 units of Shockwave Medical stock.
You can see the complete history of Kevin Ballinger stock trades at the bottom of the page.
Over the last 6 years, insiders at Shockwave Medical have traded over $488,603,927 worth of Shockwave Medical stock and bought 30,000 units worth $510,000 . The most active insiders traders include James E Deerfield Mgmt L.P...., Antoine Papiernik, and Capital Vii Fcpr Sofinnova. On average, Shockwave Medical executives and independent directors trade stock every 8 days with the average trade being worth of $10,693,924. The most recent stock trade was executed by Trinh Phung on 17 May 2024, trading 19,763 units of SWAV stock currently worth $121,740.
shockwave medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. inspired by 30-years of safety and efficacy in kidney stone treatment, our lithoplasty® family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. lithoplasty devices use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. an integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. in peripheral vascular clinical study of moderate and severely calcified lesions in 95 patients, lithoplasty technology demonstrated safety and consistent procedure success with low procedural complications. the technology is inherently familiar, easy to use, operates with just the push of a button, and works with existing cardiovascular treatmen
Shockwave Medical executives and other stock owners filed with the SEC include: